$ATLO

AMES NATIONAL CORP (ATLO): Results of Operations and Financial Condition

AMES NATIONAL CORP (ATLO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_965112.htm EXHIBIT 99.1 ex_965112.htm EXHIBIT 99.1 NEWS RELEASE CONTACT: JOHN P. NELSON FOR IMMEDIATE RELEASE CEO AND PRESIDENT (515) 232-6251 July 17, 2026 AMES NATIONAL CORPORATION ANNOUNCES EARNINGS FOR THE second QUARTER OF 2026 Ames, Iowa – Ames National Corpora

Original reporting
Published Jul 17, 2026, 8:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 17, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$ATLO
Bullish
medium confidence
Mentioned
$ATLO
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ATLOBullishMed
01

Why it matters

The core trading signal is the magnitude and drivers of net interest income and net interest margin expansion, plus a shift toward lower credit loss expense and improved efficiency.

02

Market read

Traders can reassess small-bank rate sensitivity and credit trajectory using the reported NIM, efficiency ratio, and net loan charge-offs, which may influence valuation multiples.

03

What to watch

Noninterest expense rose (professional fees, salaries/benefits) and income tax expense increased due to lower New Markets Tax Credits, which could offset operating leverage even with better NIM.

Relevance 7/10Novelty 7/10Timing: after-hours filing on 2026-07-17 following Q2 2026 results release

Background

This is an SEC Form 8-K with Exhibit 99.1 reporting Ames National Corporation’s Q2 2026 financial results and key balance-sheet metrics.

Company-level read

Ticker impact

$ATLOBullishMedium confidence
Context

Ames National reported Q2 2026 net income of $5.9M and EPS $0.67, driven by higher net interest income and margin expansion to 3.18%.

Expected impact

Near-term bias upward if investors focus on NIM expansion and reduced net loan charge-offs; downside risk if credit loss trends reverse or tax credit headwinds persist.

Evidence & confidence

The filing provides multiple directional datapoints (NIM 3.18% vs 2.65% YoY, efficiency ratio improving, net loan charge-offs down) but does not include forward guidance or management outlook beyond noting consultant fees expected to continue through 2026.

Market effects

Adds a datapoint for small-bank earnings sensitivity to rate-driven funding costs and investment yields, plus credit-loss normalization.

Limited to local/regional community banking sentiment; no cross-regional deal or regulatory action disclosed.

Low, as the disclosure is company-specific and not tied to macro policy or systemic banking events.

Counterpoint

The improvement is largely rate/yield driven (declining market rates, higher reinvestment yields), which can fade if rates reaccelerate or if loan yields compress.

Key entities

  • Ames National Corporation

    Nasdaq-listed community bank reporting Q2 2026 earnings, NIM expansion, and changes in credit loss and expenses.

Related articles

$TLRYMed

Tilray Posted Record Fiscal 2026 Revenue -- Why Isn't the Stock Rallying?

Tilray Brands reported record fiscal 2026 revenue of $915 million, up 11%, and adjusted EBITDA of $61.1 million, also up 11%. Adjusted net income nearly doubled to $12.2 million, but missed analyst estimates. GAAP net loss was $49.6 million. Management expects fiscal 2027 adjusted EBITDA of $68M-$75M. Cannabis sales represent 29% of total revenue.

$MDTMedAI 8/10

Medtronic vs. Tenet Healthcare: Which Healthcare Stock Offers Better Long-Term Growth?

Medtronic (MDT) and Tenet Healthcare (THC) present distinct growth prospects. MDT reported its highest annual revenue growth in a decade, driven by cardiac ablation solutions and investments in innovation. THC saw a 52.2% increase in adjusted EPS and 6.8% revenue growth, with margin expansion in hospitals. Investors must choose between MDT's innovation-led recovery and THC's operational improvements.

$PFEMedAI 8/10

Pfizer vs. Gilead: Which Drugmaker Has the Stronger Growth Story?

Pfizer (PFE) and Gilead (GILD) are compared on growth prospects. Pfizer's non-COVID revenue grew 5%, with key drugs like Padcev and Vyndaqel showing gains. Gilead's non-Veklury sales rose 10%, driven by HIV and oncology drugs. Both companies adjusted 2026 forecasts, with Gilead raising its outlook.

$ZTSHighAI 8/10

Zoetis Earnings Reveal a Divided Business, But Can its Pipeline Restore Growth?

Zoetis (NYSE:ZTS) reported flat Q2 2026 revenue of $2.5B, down 1% organically, with U.S. companion-animal sales declining 11% due to price sensitivity and competition. Livestock and international sales grew 12% and 8%, respectively. The company highlighted a pipeline of 12 potential blockbuster products and recent acquisitions to drive future growth.